JPMorgan Chase & Co. Has $99.96 Million Position in ICU Medical, Inc. $ICUI

JPMorgan Chase & Co. raised its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 7.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 756,383 shares of the medical instruments supplier’s stock after purchasing an additional 53,896 shares during the period. JPMorgan Chase & Co. owned 3.06% of ICU Medical worth $99,956,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Moody National Bank Trust Division increased its position in ICU Medical by 0.9% during the 2nd quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock worth $1,421,000 after buying an additional 93 shares during the period. Maryland State Retirement & Pension System raised its stake in ICU Medical by 1.8% during the second quarter. Maryland State Retirement & Pension System now owns 7,233 shares of the medical instruments supplier’s stock worth $956,000 after acquiring an additional 129 shares in the last quarter. Blue Trust Inc. increased its position in ICU Medical by 17.6% during the 2nd quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 141 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of ICU Medical by 4.4% during the second quarter. Teacher Retirement System of Texas now owns 3,548 shares of the medical instruments supplier’s stock worth $469,000 after buying an additional 148 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in ICU Medical by 3.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,280 shares of the medical instruments supplier’s stock worth $566,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Insider Buying and Selling at ICU Medical

In related news, VP Virginia Ruth Sanzone sold 930 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the completion of the transaction, the vice president directly owned 5,456 shares in the company, valued at $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares in the company, valued at $560,977.90. This represents a 24.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.50% of the company’s stock.

ICU Medical Stock Performance

Shares of ICUI opened at $149.14 on Friday. The stock’s 50-day simple moving average is $127.18 and its 200 day simple moving average is $128.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. ICU Medical, Inc. has a 52-week low of $107.00 and a 52-week high of $175.51. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of -98.12 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating the consensus estimate of $1.43 by $0.60. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. During the same quarter in the previous year, the company earned $1.59 earnings per share. ICU Medical’s revenue for the quarter was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Research analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ICUI has been the subject of several analyst reports. KeyCorp raised their target price on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Raymond James Financial lowered their price objective on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. Piper Sandler raised their target price on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wall Street Zen cut shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.